Cases & Deals

BioMarin develops gene therapy treatment for PKU

Clients BioMarin Pharmaceutical Inc.

Jones Day is representing BioMarin Pharmaceutical Inc. in its development of a phenylalanine hydroxylase ("PAH") gene therapy treatment for phenylketonuria ("PKU").

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.